Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Status:
Completed
Trial end date:
2017-07-24
Target enrollment:
Participant gender:
Summary
Primary Objective:
The primary objective is to describe the effect of insulin glargine (U300) in type 2 diabetes
mellitus (T2DM) patients uncontrolled with their current basal insulin therapy and eligible
for basal switching, according to the Physician decision, on glycated hemoglobin (HbA1c)
improvement.
Secondary Objectives:
- Evolution of fasting plasma glucose
- Evolution of insulin dose and body weight
- Hypoglycemia incidence
- Safety
- Patients satisfaction when they change their insulin for HOE901-U300